Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIDA long-term phase 3 safety extension study of SHP647 in moderate to severe ulcerative colitis
MOH_2018-01-17_002111Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ontamalimab in autoimmune colitis (2 arms), sponsored by Takeda. Primary endpoint: Safety and tolerability. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
ontamalimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2018-01-17_002111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-01-17_002111.